Flovent Diskus and Flovent HFA, which are indicated for the treatment of asthma and sometimes prescribed off-label to treat EoE, was discontinued at the end of 2023. Authorized generics of these medications will be available, however, those using these medications for EoE treatment may find that these medicines aren’t eligible for coverage through their insurance plans. APFED, other advocacy groups, and medical societies are actively educating policymakers and payors on EoE treatments used off-label and barriers to access, and requesting considerations and exemptions be made.
APFED has taken the lead in writing a communication to insurance companies and we invited other patient advocacy groups to sign on to the initiative.
In the interim, we have also prepared templates to assist with requesting an exception from insurers, for both patients and providers:
Flovent appeal letter template for providers
Flovent appeal letter template for patients
APFED is grateful to gastroenterologist Dr. Evan Dellon at University of North Carolina Chapel Hill for collaborating with on these materials.
CNN Health News Article
USA Today News Article